Astria Therapeutics’ (ATXS) Buy Rating Reaffirmed at HC Wainwright

Astria Therapeutics (NASDAQ:ATXS)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a research note issued to investors on Friday, Benzinga reports. They currently have a $16.00 price target on the biotechnology company’s stock. HC Wainwright’s price objective would suggest a potential upside of 43.88% from the stock’s current price.

Several other equities research analysts also recently commented on ATXS. Evercore ISI raised shares of Astria Therapeutics to a “strong-buy” rating in a research report on Wednesday, August 14th. Wedbush reissued an “outperform” rating and set a $22.00 price objective on shares of Astria Therapeutics in a report on Tuesday, August 13th. Oppenheimer raised their target price on Astria Therapeutics from $25.00 to $26.00 and gave the company an “outperform” rating in a report on Tuesday, August 13th. Finally, TD Cowen started coverage on Astria Therapeutics in a report on Monday, July 29th. They set a “buy” rating and a $35.00 price target for the company. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Astria Therapeutics currently has an average rating of “Buy” and a consensus price target of $25.20.

Astria Therapeutics Stock Performance

Shares of Astria Therapeutics stock opened at $11.12 on Friday. Astria Therapeutics has a 52 week low of $4.26 and a 52 week high of $16.90. The stock has a 50 day moving average price of $11.33 and a two-hundred day moving average price of $10.88. The stock has a market capitalization of $610.63 million, a PE ratio of -4.79 and a beta of 0.71.

Astria Therapeutics (NASDAQ:ATXS) last posted its quarterly earnings results on Monday, August 12th. The biotechnology company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.05). Research analysts forecast that Astria Therapeutics will post -1.66 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. RA Capital Management L.P. bought a new stake in shares of Astria Therapeutics during the 1st quarter worth $62,115,000. Perceptive Advisors LLC raised its position in Astria Therapeutics by 82.9% in the fourth quarter. Perceptive Advisors LLC now owns 4,004,070 shares of the biotechnology company’s stock worth $30,751,000 after acquiring an additional 1,814,608 shares during the period. Armistice Capital LLC purchased a new position in Astria Therapeutics in the fourth quarter valued at about $12,119,000. Artal Group S.A. bought a new position in shares of Astria Therapeutics during the 1st quarter valued at approximately $12,445,000. Finally, Nantahala Capital Management LLC bought a new position in shares of Astria Therapeutics during the 2nd quarter valued at approximately $6,142,000. Institutional investors own 98.98% of the company’s stock.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.